‘Regulatory whiplash’ as FDA decides to review Moderna flu shot

The FDA reversed course to review Moderna’s mRNA flu vaccine under an amended pathway, splitting approval requests by age group. Full approval is sought for ages 50–64, while adults 65+ face accelerated approval contingent on confirmatory trials.